Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial

Show simple item record

dc.contributor.author Albert, Michelle A.
dc.contributor.author Glynn, Robert J.
dc.contributor.author Fonseca, Francisco A. H. [UNIFESP]
dc.contributor.author Lorenzatti, Alberto J.
dc.contributor.author Ferdinand, Keith C.
dc.contributor.author MacFadyen, Jean G.
dc.contributor.author Ridker, Paul M.
dc.date.accessioned 2016-01-24T14:16:57Z
dc.date.available 2016-01-24T14:16:57Z
dc.date.issued 2011-07-01
dc.identifier http://dx.doi.org/10.1016/j.ahj.2011.03.032
dc.identifier.citation American Heart Journal. New York: Mosby-Elsevier, v. 162, n. 1, p. 106-U147, 2011.
dc.identifier.issn 0002-8703
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/33850
dc.description.abstract Objectives the aim of this study was to evaluate the effect of statin treatment in primary prevention of cardiovascular events in different race/ethnic groups.Background Clinical trial evidence about the efficacy of statins in the primary prevention of cardiovascular events among nonwhites is uncertain.Methods JUPITER trial, a randomized, double-blind, placebo-controlled evaluation of rosuvastatin 20 mg in the primary prevention of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death included 12,683 whites and 5,117 nonwhites with low-density lipoprotein levels <130 mg/dL and high-sensitivity C-reactive protein levels >= 2.0 mg/L.Results Random allocation to rosuvastatin resulted in a 45% reduction in the primary end point among whites (hazard ratio [HR] 0.55, 95% CI 0.43-0.69) and a 37% reduction among nonwhites (HR 0.63, 95% CI 0.41-0.99). Blacks (HR 0.65, 95% CI 0.35-1.22) and Hispanics (HR 0.58, 95% CI 0.25-1.39) had similar risk reductions. Among nonwhites in the placebo group, the stroke rate exceeded the MI rate (0.44 vs 0.20 per 100 person-years); an opposite pattern was observed among whites (0.31 vs 0.42 per 100 person-years). Nonwhites had higher death rates than whites (2.25 vs 0.93 per 100 person-years); however, all-cause mortality was similar at 20% with rosuvastatin treatment in both participant groups.Conclusions When used in primary prevention among individuals with low-density lipoprotein <130 mg/dL and high-sensitivity C-reactive protein >= 2 mg/L, rosuvastatin significantly reduced first MI, stroke, arterial revascularization, hospitalization for unstable angina, and cardiovascular death among whites and nonwhites. (Am Heart J 2011;162:106-114.e2.) en
dc.description.sponsorship Astra-Zeneca
dc.description.sponsorship Lerner Cardiovascular Award
dc.description.sponsorship Doris Duke and Donald W. Reynolds Foundations
dc.description.sponsorship Merck
dc.description.sponsorship Association of Black Cardiologists
dc.description.sponsorship Vascular Biology Working Group
dc.description.sponsorship Novartis
dc.description.sponsorship Abbott
dc.description.sponsorship Roche
dc.description.sponsorship SanofiAventis
dc.description.sponsorship MerckSchering- Plough
dc.description.sponsorship Sanofi-Aventis
dc.description.sponsorship Isis
dc.description.sponsorship Dade Behring
dc.description.sponsorship Vascular Biogenics
dc.description.sponsorship Bristol Myers-Squibb
dc.description.sponsorship Takeda
dc.description.sponsorship Pfizer
dc.description.sponsorship Forest Laboratories
dc.description.sponsorship Daiichi Sankyo Inc
dc.format.extent 106-U147
dc.language.iso eng
dc.publisher Elsevier B.V.
dc.relation.ispartof American Heart Journal
dc.rights Acesso restrito
dc.title Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial en
dc.type Artigo
dc.rights.license http://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.contributor.institution Harvard Univ
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.contributor.institution Hosp Cordoba
dc.contributor.institution Emory Univ
dc.description.affiliation Harvard Univ, Brigham & Womens Hosp, Donald W Reynolds Ctr Cardiovasc Dis Res,Sch Med, Div Cardiovasc Dis,Ctr Cardiovasc Dis Prevent, Boston, MA 02115 USA
dc.description.affiliation Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA
dc.description.affiliation Universidade Federal de São Paulo, Disciplina Cardiol, Setor Lipides Aterosclerose & Biol Vasc, São Paulo, Brazil
dc.description.affiliation Hosp Cordoba, Cordoba, Argentina
dc.description.affiliation Emory Univ, Div Cardiol, Atlanta, GA 30322 USA
dc.description.affiliationUnifesp Universidade Federal de São Paulo, Disciplina Cardiol, Setor Lipides Aterosclerose & Biol Vasc, São Paulo, Brazil
dc.identifier.doi 10.1016/j.ahj.2011.03.032
dc.description.source Web of Science
dc.identifier.wos WOS:000292542400024



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account